Updated July 11, 2026
Daraxonrasib pancreatic cancer research has created new hope for patients with previously treated metastatic pancreatic ductal adenocarcinoma. In the phase 3 RASolute 302 trial, daraxonrasib significantly improved overall survival, progression-free survival and tumor response compared with standard chemotherapy [1–3]. However, daraxonrasib remained an investigational pancreatic cancer treatment as of July 2026 and should not be described as an approved cure.
That result is clinically important. However, it needs to be understood carefully. Daraxonrasib is not yet an approved pancreatic cancer medicine, and the study did not show that it cures metastatic pancreatic cancer. In the United States, the Food and Drug Administration has allowed an expanded-access program for certain eligible patients, while a rolling New Drug Application was still nearing completion as of July 7, 2026 [4–6]. The European Medicines Agency has also started a phased review, but this is not the same as marketing authorization.
For patients and families, the most important questions are now practical: Who might be eligible? How large was the benefit? What side effects occurred? How can patients in the United States, United Kingdom, Canada, Australia and Singapore ask about access? And can supportive approaches such as Ayurveda be integrated safely?
What is daraxonrasib?
Daraxonrasib, previously known as RMC-6236, is an oral targeted therapy designed to block RAS proteins while they are in their active, or “on,” state. It is described as a RAS(ON) multi-selective inhibitor because it is intended to suppress signaling from several mutant forms of RAS as well as active wild-type RAS [1,3].
RAS proteins function like cellular switches. When functioning normally, they help regulate cell growth. In many pancreatic cancers, mutations cause the switch to remain active, sending continuous signals that encourage cancer cells to grow and survive. More than 90% of pancreatic ductal adenocarcinomas are associated with RAS mutations, most commonly involving KRAS [3,18].
Earlier targeted drugs were usually designed for one particular KRAS mutation. Daraxonrasib takes a broader approach. It forms a complex that interferes with active RAS signaling and its downstream effects. This is one reason it may be relevant to more pancreatic cancer patients than a mutation-specific inhibitor.
Daraxonrasib is still an investigational medicine. Patients should not buy products advertised under this name online, alter their existing treatment or attempt to obtain an unregulated version.
What did the RASolute 302 trial find?
RASolute 302 was a global, randomized, open-label phase 3 study involving 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. A total of 248 participants received oral daraxonrasib once daily, while 252 received the investigator’s choice of four established chemotherapy regimens [1–3].
The trial included people with RAS G12-mutated tumors and people without an identified tumor RAS mutation. At the February 10, 2026 data cut-off, median follow-up was 8.5 months.
Daraxonrasib phase 3 results at a glance
| Study outcome | Daraxonrasib | Chemotherapy | What the result means |
|---|---|---|---|
| Median overall survival | 13.2 months | 6.7 months | Half the patients lived longer and half lived for a shorter period than the median |
| Median progression-free survival | 7.2 months | 3.6 months | Daraxonrasib delayed cancer progression or death compared with chemotherapy |
| Objective response rate | 31.6% | 11.2% | Approximately one in three daraxonrasib patients had measurable tumor shrinkage |
| Grade 3 or higher treatment-related adverse events | 43.6% | 57.5% | Serious treatment-related side effects remained common but occurred less often overall |
| Treatment stopped because of treatment-related side effects | 1.2% | 11.2% | Far fewer patients discontinued daraxonrasib because of toxicity |
| Time to worsening pain | Hazard ratio 0.51 | Reference group | Patient-reported pain took longer to deteriorate with daraxonrasib |
| Time to deterioration in global health and quality of life | Hazard ratio 0.60 | Reference group | Overall health and quality of life were preserved for longer |
Source: RASolute 302 intention-to-treat population [1–3].
The hazard ratio for death was 0.40. In statistical terms, this represents a 60% relative reduction in the risk of death during the study follow-up period. It does not mean that 60% of patients were cured or that every patient gained an additional 6.5 months of life.
Results were similar in the trial’s RAS G12 subgroup. Median overall survival was 13.2 months with daraxonrasib and 6.6 months with chemotherapy. Median progression-free survival was 7.3 months and 3.5 months, respectively, while response rates were 33.2% and 11.8% [1,3].
Why these findings matter
Second-line treatment options for metastatic pancreatic cancer have historically produced limited benefits and can be difficult to tolerate. Daraxonrasib improved overall survival, progression-free survival, tumor response and patient-reported quality of life in the same randomized trial. That combination makes the result more meaningful than tumor shrinkage alone.
The oral administration may also be attractive to patients who have already spent months receiving intravenous treatment. Nevertheless, an oral cancer drug is not automatically a mild treatment. Daraxonrasib caused clinically significant toxicity, required monitoring and was tested in patients who met specific health and performance-status requirements.
The study was also limited to previously treated metastatic pancreatic ductal adenocarcinoma. Its results cannot automatically be applied to newly diagnosed metastatic disease, locally advanced cancer, pancreatic neuroendocrine tumors or patients receiving treatment after potentially curative surgery.
The median follow-up was still relatively short when the results were reported. Longer follow-up will be needed to understand the durability of responses and whether a small group of patients receives unusually prolonged benefit. Pancreatic cancer can also develop resistance to targeted therapy, meaning that daraxonrasib should be viewed as a substantial treatment advance rather than an established cure [18].
What are the possible daraxonrasib side effects?
The most frequent severe treatment-related side effects in RASolute 302 were rash, occurring in approximately 14% of daraxonrasib patients, and stomatitis or inflammation and sores inside the mouth, occurring in approximately 12%. Diarrhea, nausea and vomiting were also reported [1,3].
One treatment-related death from pneumonitis, a serious inflammation of the lungs, occurred in the daraxonrasib group. Although this was uncommon, patients should urgently report new shortness of breath, a persistent cough, fever, chest discomfort or an unexplained fall in oxygen levels.
Rashes and mouth soreness are often more manageable when reported early. Patients should tell their treatment team as soon as symptoms appear instead of waiting until eating, drinking or sleeping becomes difficult. Diarrhea can lead to dehydration and electrolyte disturbances, particularly in people who are already losing weight or struggling to maintain nutrition.
Patients should not reduce the dose, stop treatment, begin an over-the-counter remedy or add an herbal product without speaking to the trial or expanded-access team. Investigational medicines are generally managed under detailed protocols, and apparently natural products may alter drug exposure or add liver, kidney, bleeding or gastrointestinal risks.
Who might be eligible for daraxonrasib?
The strongest evidence currently applies to adults with metastatic pancreatic ductal adenocarcinoma who have already received a systemic treatment containing either a fluoropyrimidine or gemcitabine.
The U.S. expanded-access program is intended for eligible adults whose cancer has progressed, who could not tolerate standard treatment, or who are no longer expected to benefit from available standard therapies. Patients must also be unable to enter another daraxonrasib clinical trial. Organ function, ability to take oral medicine, general fitness and other medical conditions are assessed before enrollment [4,5].
Some exclusion criteria may include active central nervous system metastases, serious cardiovascular disease, uncontrolled infection, concurrent systemic anticancer treatment or gastrointestinal conditions that could prevent adequate absorption. A previous Whipple procedure does not automatically make a patient ineligible, although the complete current criteria must be checked by the treating physician [5].
A particular RAS mutation was not required for enrollment in RASolute 302. Documented tumor RAS status was collected, and the study enrolled patients with or without an identified mutation [1–3]. Molecular profiling is still important because it may reveal other treatment options, hereditary risks or clinical trials. A future approved label could also differ from the phase 3 eligibility criteria.
The 300 mg once-daily dose used in RASolute 302 is a clinical-trial dose, not a self-treatment recommendation. Only the study, expanded-access or eventual approved prescribing protocol should determine an individual patient’s dose.
Is daraxonrasib FDA approved?
As of July 11, 2026, daraxonrasib remained investigational. The FDA had issued a “safe to proceed” letter for an expanded-access treatment protocol on April 30, announced publicly on May 1, 2026 [4]. This action permits eligible U.S. patients to receive the drug before possible commercial approval, but it does not mean the FDA has determined that the drug is approved for general prescribing.
The FDA previously granted daraxonrasib Breakthrough Therapy and Orphan Drug designations. It was also selected for the Commissioner’s National Priority Voucher pilot program. On July 7, Revolution Medicines reported that its rolling U.S. New Drug Application was nearing completion [4,6].
In Europe, the EMA’s Committee for Medicinal Products for Human Use began a phased review. During this process, sections of the evidence can be reviewed before a complete marketing application is filed. That may accelerate assessment, but it is not an approval decision [6].
Daraxonrasib access in the USA, UK, Canada, Australia and Singapore
Access rules differ by country. A national pathway for an unapproved medicine does not guarantee that daraxonrasib will be supplied. The manufacturer must agree to provide the drug, an eligible treating institution must accept clinical responsibility, and local regulatory, import, pharmacy and monitoring requirements must be satisfied.
| Country | Position as of July 11, 2026 | Possible patient pathway |
|---|---|---|
| United States | Not approved for routine sale; expanded-access protocol permitted by the FDA | A U.S.-licensed oncologist can assess eligibility and submit a request through the sponsor’s expanded-access program, NCT07573215 [4,5] |
| United Kingdom | No routine UK authorization established in the cited public updates | The treating oncology center can check clinical trials and whether a sponsor-supported route under the MHRA Early Access to Medicines Scheme is available [10] |
| Canada | Not a routinely marketed medicine | A Canadian practitioner may ask Health Canada’s Special Access Program to authorize an unapproved drug for a serious or life-threatening condition when conventional options have failed, are unsuitable or are unavailable [11] |
| Australia | Not a routinely approved therapeutic good | A registered practitioner may consider the TGA Special Access Scheme; regulatory permission does not mean the TGA will obtain or supply the medicine [12] |
| Singapore | Not a routinely registered therapeutic product | A licensed hospital or clinic may seek HSA Special Access Route approval for a named patient with an unmet need; investigational products require clinical justification, consent and appropriate professional support [13] |
The EMA phased review should not be interpreted as UK approval. Medicines in the United Kingdom are regulated through the Medicines and Healthcare products Regulatory Agency. The UK Early Access to Medicines Scheme applies only when its specific regulatory and sponsor requirements have been met [6,10].
Patients should not abandon an effective current treatment while waiting for daraxonrasib. The most productive next step is to ask a pancreatic cancer specialist whether the patient fits the evidence-based population, whether a clinical trial is available and whether the appropriate national access route is realistic.
Is daraxonrasib being studied as first-line treatment?
Yes, but the first-line evidence is preliminary.
In an early phase 1/2 cohort of 40 previously untreated patients with RAS-mutated metastatic pancreatic cancer, daraxonrasib combined with gemcitabine and nab-paclitaxel produced a confirmed response rate of 58%. Estimated six-month progression-free and overall survival rates were 84% and 90%, respectively. Median survival results were not yet mature [7].
In a separate first-line monotherapy cohort, the reported response rate was 47%, with a disease-control rate of 92%. Estimated six-month progression-free and overall survival rates were 71% and 83%. These were small, open-label early-phase cohorts and should not be compared directly with a randomized control group [7].
The phase 3 RASolute 303 trial, NCT07491445, is evaluating daraxonrasib alone, daraxonrasib plus gemcitabine and nab-paclitaxel, and chemotherapy alone in previously untreated metastatic pancreatic cancer [8]. Another phase 3 study, RASolute 304, NCT07252232, is evaluating daraxonrasib after surgery and perioperative chemotherapy in resected pancreatic ductal adenocarcinoma [9].
Until these trials report results, daraxonrasib should not be presented as a proven first-line or post-surgery treatment.
Can Ayurveda help alongside daraxonrasib?
Ayurveda may have a constructive role in supportive, whole-person cancer care, provided it is integrated with oncology rather than used to replace it.
The most responsible goal is not to claim that an Ayurvedic formula eliminates pancreatic cancer. It is to help a patient maintain daily structure, nourishment, sleep, emotional stability, gentle physical activity and a sense of participation in care. For a person living with pancreatic cancer, these aspects can matter greatly.
An Ayurveda-informed supportive plan may include culturally appropriate food choices, regular sleep and meal timings, breathing or relaxation exercises, mindfulness, carefully adapted yoga and attention to symptoms such as fatigue, stress and reduced appetite. The plan should be coordinated with the oncologist, oncology dietitian and pharmacist. Restrictive fasting, aggressive “detoxification,” purgation or any regimen likely to worsen weight loss or dehydration should be avoided in medically fragile patients.
The strongest evidence in integrative oncology is generally for non-drug approaches rather than herbal anticancer claims. The joint ASCO–Society for Integrative Oncology guideline recommends interventions including exercise, cognitive behavioral therapy, mindfulness programs and tai chi or qigong for cancer-related fatigue [15]. These approaches do not control the tumor, but they may help selected patients cope with the physical and emotional burden of treatment.
A 2026 AACR conference abstract described a retrospective study of 17 patients with advanced, inoperable pancreatic cancer who were considered ineligible for chemotherapy. Investigators reported improvements in quality-of-life, performance-status and anorexia measures after Ayurvedic Rasayana Therapy. Average survival was reported as 316 days, and two partial tumor responses were recorded [17].
These results are interesting but cannot establish that Ayurveda caused the reported outcomes. The study was retrospective, had only 17 participants, had no randomized control group and was published as a conference abstract. It is therefore hypothesis-generating evidence that supports further research, not proof of survival benefit or a pancreatic cancer cure. Some of the formulations described also included mineral or metal preparations, making independent quality and contamination testing particularly important.
The U.S. National Center for Complementary and Integrative Health states that there is little scientific evidence supporting Ayurveda for most health conditions. It also warns that some preparations may contain toxic quantities of lead, mercury or arsenic [14]. The National Cancer Institute concludes that current evidence is inadequate to recommend curcumin products as cancer treatment or as an adjunct intended to treat cancer. Severe liver toxicity has also been reported with some products labeled as containing curcumin [16].
This is especially important with daraxonrasib because the medicine is investigational and its complete herb–drug interaction profile is not yet established in an approved prescribing label. Every herb, powder, bhasma, supplement, tea and concentrated extract should be disclosed to the trial or expanded-access team. Patients should obtain written approval before adding any such product.
Readers exploring a coordinated Ayurveda-informed approach can review Panaceayur Ayurveda’s information here:
Ayurveda-informed support for pancreatic cancer
This page should be used as a starting point for a discussion with qualified practitioners and the oncology team. It is not a substitute for surgery, chemotherapy, radiotherapy, targeted treatment, clinical-trial participation or urgent medical care.
The most credible integrative model is oncology-led and Ayurveda-informed: cancer-directed decisions remain with the oncology team, while carefully selected supportive practices are used to strengthen day-to-day care and quality of life.
Questions patients should ask their oncologist
Patients can ask whether the pathology confirms pancreatic ductal adenocarcinoma; whether the disease and prior treatment match the RASolute 302 population; whether molecular profiling has been completed; whether the patient could enter RASolute 303, RASolute 304 or another relevant study; whether U.S. expanded access or a national unapproved-medicine pathway is realistic; how rash, mouth sores, diarrhea and possible lung inflammation will be monitored; which herbs and supplements must be stopped; and what travel, hospital, pharmacy or monitoring costs may remain even when an investigational drug is supplied.
Bringing a complete medication and supplement list to the appointment can prevent avoidable interactions. Patients should include products used only occasionally and products considered “food,” especially concentrated turmeric or curcumin, herbal mixtures and metal-containing preparations.
Frequently asked questions
Is daraxonrasib a cure for pancreatic cancer?
No. Daraxonrasib substantially improved median survival, progression-free survival and response rates in previously treated metastatic pancreatic cancer, but the trial did not establish a cure. Most participants did not have complete disappearance of their cancer, and resistance or later progression remains possible [1,18].
Has daraxonrasib been approved by the FDA?
Not as of July 11, 2026. The FDA has permitted an expanded-access protocol for eligible U.S. patients, and the manufacturer’s rolling New Drug Application was reported to be nearing completion on July 7, 2026 [4–6].
Is daraxonrasib chemotherapy?
No. It is an oral targeted RAS(ON) inhibitor. It works differently from traditional cytotoxic chemotherapy, although it still causes side effects and requires specialist monitoring.
Does a patient need a KRAS mutation?
RASolute 302 enrolled patients with or without an identified tumor RAS mutation, and benefit was reported in both the RAS G12 population and the overall population [1–3]. Molecular testing remains important, and final eligibility or an eventual approved indication may differ from the trial criteria.
Can daraxonrasib be used as a first treatment?
It is being studied in first-line metastatic pancreatic cancer, but first-line benefit has not yet been confirmed in a completed randomized phase 3 trial. RASolute 303 is designed to answer this question [7,8].
Can daraxonrasib be used after pancreatic cancer surgery?
That use remains experimental. RASolute 304 is studying daraxonrasib in patients with resected pancreatic ductal adenocarcinoma after surgery and perioperative chemotherapy [9].
Can Ayurveda cure pancreatic cancer?
There is no reliable randomized clinical evidence showing that Ayurveda cures pancreatic cancer. Its most defensible role is as carefully coordinated supportive care intended to improve routines, coping and quality of life without delaying or replacing oncology treatment [14–17].
Can Ayurvedic herbs be taken with daraxonrasib?
They should not be started without approval from the treating oncology team. The complete interaction profile is not established, and some products may affect the liver, gastrointestinal system, blood clotting or drug metabolism. Some Ayurvedic preparations may also contain toxic metals [14,16].
The bottom line
Daraxonrasib is one of the most significant recent clinical developments for previously treated metastatic pancreatic ductal adenocarcinoma. In a 500-patient phase 3 trial, it nearly doubled median overall survival compared with chemotherapy while producing fewer severe treatment-related events and fewer treatment discontinuations.
The drug nevertheless remains investigational. Expanded access in the United States is not FDA approval, and special-access pathways in other countries do not guarantee supply. Patients should discuss eligibility with a pancreatic cancer specialist and should not delay an available standard treatment while waiting.
Ayurveda can be positioned credibly as part of coordinated supportive care, with attention to nutrition, daily routine, fatigue, stress and quality of life. It should never be presented as a proven substitute for tumor-directed treatment, and every herbal or mineral preparation must be reviewed for safety and possible interaction.
Medical disclaimer: This article provides general educational information and does not diagnose disease, determine eligibility or recommend an individual treatment. Drug status and clinical-trial criteria can change. Patients should verify current information with their oncologist, relevant regulator and trial sponsor.
References
- O’Reilly EM, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. The New England Journal of Medicine, 2026. Primary publication of the randomized RASolute 302 phase 3 trial.
https://www.nejm.org/doi/full/10.1056/NEJMoa2605555 - ClinicalTrials.gov. NCT06625320: Phase 3 Study of Daraxonrasib in Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma. Trial design, population and study status.
https://clinicaltrials.gov/study/NCT06625320 - Revolution Medicines. RASolute 302 ASCO Plenary Presentation and Detailed Phase 3 Results, May 31, 2026. Provides survival, response, safety and patient-reported outcome data.
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-asco-plenary-presentation - U.S. Food and Drug Administration. FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug, May 1, 2026. Official FDA explanation of the daraxonrasib expanded-access action.
https://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug - ClinicalTrials.gov. NCT07573215: Expanded Access Program for Daraxonrasib. Current program description and eligibility information for previously treated metastatic pancreatic adenocarcinoma.
https://clinicaltrials.gov/study/NCT07573215 - Revolution Medicines. European Medicines Agency Begins Phased Review of Daraxonrasib, July 7, 2026. Also reports that the rolling U.S. NDA submission was nearing completion.
https://ir.revmed.com/news-releases/news-release-details/european-medicines-agency-expedites-assessment-revolution - Revolution Medicines. Updated Phase 1/2 First-Line Daraxonrasib Data, April 21, 2026. Preliminary monotherapy and combination results in previously untreated metastatic pancreatic cancer.
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-present-updated-phase-12-clinical-data/ - ClinicalTrials.gov. NCT07491445: RASolute 303. Phase 3 first-line study of daraxonrasib alone or with gemcitabine and nab-paclitaxel.
https://clinicaltrials.gov/study/NCT07491445 - ClinicalTrials.gov. NCT07252232: RASolute 304. Phase 3 study of daraxonrasib in resected pancreatic ductal adenocarcinoma.
https://clinicaltrials.gov/study/NCT07252232 - UK Medicines and Healthcare products Regulatory Agency. Early Access to Medicines Scheme. Explains the UK pathway for certain medicines without marketing authorization.
https://www.gov.uk/guidance/apply-for-the-early-access-to-medicines-scheme-eams - Health Canada. Request a Drug Through the Special Access Program. Official practitioner-led process for medicines unavailable for sale in Canada.
https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html - Australian Therapeutic Goods Administration. Special Access Scheme for Individual Patients. Official pathway for accessing unapproved therapeutic goods.
https://www.tga.gov.au/business-services/special-access-scheme-and-authorised-prescriber-online-system/access-unapproved-therapeutic-goods-individual-patients-special-access-scheme - Singapore Health Sciences Authority. Import and Supply of Unregistered Therapeutic Products for Patient Use. Requirements for named-patient special access.
https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/special-access-routes/import-for-patients/ - National Center for Complementary and Integrative Health. Ayurvedic Medicine: In Depth. Reviews the limited evidence base and risks including possible heavy-metal exposure.
https://www.nccih.nih.gov/health/ayurvedic-medicine-in-depth - Bower JE, et al. Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update. Evidence-based recommendations for exercise and selected mind-body interventions.
https://ascopubs.org/doi/10.1200/JCO.24.00541 - National Cancer Institute. Curcumin and Cancer, PDQ Health Professional Version. Reviews cancer evidence, study limitations and reported safety concerns.
https://www.cancer.gov/about-cancer/treatment/cam/hp/curcumin-pdq - Bendale Y, et al. Clinical Outcomes of Ayurveda Rasayana Therapy in Advanced Pancreatic Cancer Patients: A Retrospective Study. AACR 2026 abstract involving 17 patients; preliminary, uncontrolled evidence.
https://aacrjournals.org/cancerres/article/86/7_Supplement/1239/777466/Abstract-1239-Clinical-outcomes-of-Ayurveda - Stanford Medicine. A Pancreatic Cancer Drug Provides New Hope: Five Things to Know, June 24, 2026. Independent clinical explanation of daraxonrasib, its potential and remaining limitations.
https://med.stanford.edu/news/insights/2026/06/pancreatic-cancer-drug-daraxonrasib-what-to-know.html
